Skip to main content
Medical information Clinical review pending

Cytogenetics

Lung Cancer Panel 4 EGFR ALK1 ROS1 MET PD L1

The Lung Cancer Panel 4 test identifies specific genetic mutations (EGFR, ALK1, ROS1, MET, PD L1) in lung cancer tissue. This helps guide personalized treatment decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Tumor tissue sample (biopsy or surgical resection). Confirm specific requirements with the laboratory before booking.
Results
Results are typically available within 5-7 days. Confirm exact turnaround time with the laboratory before booking.
Preparation
No specific patient preparation is required. A doctor's prescription is needed.
Test priceKSh 60,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Lung Cancer Panel 4 EGFR ALK1 ROS1 MET PD L1 test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients diagnosed with non-small cell lung cancer (NSCLC).
  • ✓Individuals with symptoms suggestive of lung cancer.
  • ✓Patients with risk factors for lung cancer (e.g., smoking history).
  • ✓Guiding treatment decisions for lung cancer.
  • ✓Determining eligibility for targeted therapies.
02

In plain language

What this test helps you understand

Identifies specific genetic mutations in lung cancer tissue to guide personalized treatment strategies and predict response to targeted therapies.
The Lung Cancer Panel 4 test is a diagnostic tool used to identify specific genetic mutations associated with lung cancer. Analyzing tumor tissue, this test looks for alterations in genes like EGFR, ALK1, ROS1, MET, and PD L1. Understanding these mutations is crucial for tailoring treatment plans and improving patient outcomes.

This test measures the presence of genetic alterations in key components relevant to lung cancer: - EGFR (Epidermal Growth Factor Receptor) - ALK1 (Anaplastic Lymphoma Kinase) - ROS1 (ROS Proto-Oncogene 1) - MET (Mesenchymal-Epithelial Transition Factor) - PD L1 (Programmed Death-Ligand 1)

Identifying these mutations helps determine the most effective targeted therapies for lung cancer patients.

This test is recommended for individuals with symptoms suggestive of lung cancer, those with risk factors like a smoking history or family history, or patients already diagnosed with lung cancer seeking to guide treatment options.

The Lung Cancer Panel 4 test offers benefits such as personalized treatment plans, informed decision-making for healthcare providers, and potentially improved survival rates. Results provide insights into the cancer's genetic makeup, indicating eligibility for targeted therapies or guiding alternative treatment options. Your healthcare provider will interpret the results with you.

We have branches across Kenya and offer home sample collection services. Contact us at +254711564616 to book the test or for more information.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. A doctor's prescription is needed.
SampleTumor tissue sample (biopsy or surgical resection). Confirm specific requirements with the laboratory before booking.
MethodologyMolecular testing techniques, such as Next Generation Sequencing (NGS) or Polymerase Chain Reaction (PCR), are used to detect the specified genetic mutations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
The test analyzes specific mutations; it may not detect all possible genetic alterations. Results should be interpreted in the context of the patient's overall clinical picture. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test looks for specific genetic mutations (EGFR, ALK1, ROS1, MET, PD L1) in lung cancer cells that can influence treatment options.
This test is primarily for individuals diagnosed with lung cancer, particularly non-small cell lung cancer, to help guide treatment decisions.
A sample of the tumor tissue, usually obtained through a biopsy or surgery, is required for this test.
Results are typically available within 5-7 days, but this can vary. Please confirm the current turnaround time with the laboratory.
Insurance coverage varies. Please check with your insurance provider regarding coverage for this specific test.
You can book the test by contacting us at +254711564616. A doctor's prescription is required.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp